Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Everolimus in Refractory Meningioma
NCT00972335Phase 2Terminated
- Sponsor
- SCRI Development Innovations
- Start
- Jan 2010
- Primary completion
- Jul 2014
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, everolimus in meningioma, sponsored by SCRI Development Innovations. Started Jan 2010; status: terminated.
02
Drugs
bevacizumabeverolimus
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT00972335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00972335.